BriaCell Therapeutics Corp.
TSX:BCT.TOBiotechnology
+$0.94 today
- Market cap
- $50.02M
- Beta
- 1.53
- P/E (TTM)
- -0.3
- EPS (TTM)
- -$4.23
Volume 0.00M
Average 0.01M
BCT.TO Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
BriaCell Therapeutics Corp.TSX: BCT.TO
Change in Working Capital · Q3 FY2026 · quarter ended Apr 2026
Change in working capital turns positive
Q3 FY2026 change in working capital was $95.69K, compared with -$1.08M a year earlier. Trailing-twelve-month change in working capital was -$176.23K. Over 3 fiscal years it compounded at +70.2% a year.
Context
- Change in working capital increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly change in working capital holds near $95.69K or moves back toward the trailing-twelve-month quarterly average of -$44.06K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (1.93M) USD
- Year-over-year change
- -127.4%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | (1.93M) | -127.4% |
| FY2024 | 2024-07-31 | 7.05M | +299.7% |
| FY2023 | 2023-07-31 | (3.53M) | -802.6% |
| FY2022 | 2022-07-31 | (391.29K) | +82.9% |
| FY2021 | 2021-07-31 | (2.28M) | — |
Change in Working Capital vs competitors
How BCT.TO compares with its peers on the latest reported figures
No competitor Change in Working Capital figures are available to compare.
Cash Flow Statement
Metric | FY2021 Jul 2021 | FY2022 Jul 2022 | FY2023 Jul 2023 | FY2024 Jul 2024 | FY2025 Jul 2025 |
|---|---|---|---|---|---|
| Net Income | (13.82M) | (26.84M) | (20.3M) | (4.93M) | (26.63M) |
| Depreciation & Amortization | 15.26K | 15.27K | 15.27K | 83.9K | 107.93K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.97M | 3.07M | 2.19M | 1.8M | 0 |
| Change in Working Capital | (2.28M) | (391.29K) | (3.53M) | 7.05M | (1.93M) |
| Accounts Receivables | 9.94K | (11.53K) | 5.23K | (732.58K) | 742.6K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.41M) | 249.16K | 660.46K | 6.05M | (3.93M) |
| Other Working Capital | (886.38K) | (628.93K) | (4.2M) | 1.74M | 1.26M |
| Other Non-Cash Items | 6.36M | 11.66M | (2.12M) | (28.14M) | (58.73K) |
| Operating Cash Flow | (7.75M) | (12.48M) | (23.74M) | (24.13M) | (28.51M) |
| Capital Expenditures | 0 | 0 | 0 | (456.8K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | (225K) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (7.74M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (681.8K) | (7.74M) |
| Debt Repayment | (330.4K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 51.62M | 0 | 4M | 4.42M | 46M |
| Common Stock Repurchased | 0 | (10.17M) | (47.29K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 13.71M | 6.43M | 1.59K | 0 | 0 |
| Financing Cash Flow | 65M | (3.74M) | 3.95M | 4.42M | 46M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (84.08K) |
| Net Change in Cash | 57.25M | (16.23M) | (19.79M) | (20.39M) | 9.67M |
| Free Cash Flow | (7.75M) | (12.48M) | (23.74M) | (24.58M) | (28.51M) |
BriaCell Therapeutics Corp.
TSX:BCT.TO
Intrinsic Alpha fair value
Locked
Current Price
$5.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.